Paclitaxel

Name: Paclitaxel
Brand: Selleck Chemicals
SKU: S1150
Rating: 5 (125 reviews)

For research use only. Not for use in humans.

Catalog No.S1150 Synonyms: NSC 125973

125 publications

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Selleck's Paclitaxel has been cited by 125 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Adv Mater, 2018, 30(43):e1801621

PubMed: 30203567 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(5):650-664

PubMed: 29100014 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):238-250

PubMed: 30664790 ( click the link to review the publication )

Nat Commun, 2019, 10(1):620

PubMed: 30728358 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0441-3

PubMed: 31645676 ( click the link to review the publication )

Cell Death Differ, 2019, 26(11):2300-2313

PubMed: 30778200 ( click the link to review the publication )

J Control Release, 2019, 294:165-175

PubMed: 30557650 ( click the link to review the publication )

Redox Biol, 2019, 22:101131

PubMed: 30735911 ( click the link to review the publication )

Oncogene, 2019, 38(18):3371-3386

PubMed: 30635656 ( click the link to review the publication )

Oncogene, 2019, 38(18):3371-3386

PubMed: 30635656 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(12):2079-2094

PubMed: 30825187 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31766723 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):64

PubMed: 31101119 ( click the link to review the publication )
Cell Death Dis, 2019, 10(9):660

PubMed: 31506430 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31295851 ( click the link to review the publication )

Cancer Biomark, 2019, 10.3233/CBM-190460

PubMed: 31683459 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0923

PubMed: 31160383 ( click the link to review the publication )

J Virol, 2019, 93(4)

PubMed: 30487274 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(46):17471-17486

PubMed: 31594861 ( click the link to review the publication )

J Biol Chem, 2019, 294(20):8161-8170

PubMed: 30940730 ( click the link to review the publication )

J Biol Chem, 2019, 10.1074/jbc.RA119.010732

PubMed: 31628188 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(6):711-719

PubMed: 31585985 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2019, 183:110396

PubMed: 31394424 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 498:110585

PubMed: 31536779 ( click the link to review the publication )

Life Sci, 2019, 224:255-262

PubMed: 30928404 ( click the link to review the publication )

Cell Biosci, 2019, 9:20

PubMed: 30820314 ( click the link to review the publication )

Chem Biol Interact, 2019, 315:108886

PubMed: 31682804 ( click the link to review the publication )

Biomed Rep, 2019, 10(4):218-224

PubMed: 30972217 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

AAPS PharmSciTech, 2019, 20(5):198

PubMed: 31127389 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1154-1159

PubMed: 31103263 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(10):152606

PubMed: 31500928 ( click the link to review the publication )
Orthop Surg, 2019, 11(1):126-134

PubMed: 30592172 ( click the link to review the publication )

Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

World J Clin Oncol, 2019, 10(6):222-233

PubMed: 31367531 ( click the link to review the publication )

Oncotarget, 2019, 10(38):3667-3680

PubMed: 31217901 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4116

PubMed: 30297712 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(8):e8238

PubMed: 30104419 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Control Release, 2018, 283:223-234

PubMed: 29864473 ( click the link to review the publication )

Cancer Lett, 2018, 420:60-71

PubMed: 29408653 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):743

PubMed: 29970890 ( click the link to review the publication )

J Clin Med, 2018, 7(12)

PubMed: 30477228 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1134

PubMed: 30429459 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(2):489-504

PubMed: 29794416 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(5):2046-2060

PubMed: 30099455 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

J Cell Sci, 2018, 131(1)

PubMed: 29192060 ( click the link to review the publication )

Biochem Pharmacol, 2018, 155:102-109

PubMed: 29953843 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(10)

PubMed: 30326563 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1116

PubMed: 30319428 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1225

PubMed: 30526520 ( click the link to review the publication )
Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )

Fitoterapia, 2018, 125:174-183

PubMed: 29355751 ( click the link to review the publication )

Int J Med Sci, 2018, 15(7):738-747

PubMed: 29910679 ( click the link to review the publication )

DNA Repair (Amst), 2018, 63:1-9

PubMed: 29358095 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

Clin Chem, 2017, 63(10):1633-1641

PubMed: 28784692 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(6):1617-1629

PubMed: 28552603 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(7):1377-1388

PubMed: 28416606 ( click the link to review the publication )

J Cancer, 2017, 8(9):1655-1664

PubMed: 28775785 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

Respir Res, 2017, 18(1):52

PubMed: 28340578 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:146

PubMed: 28491824 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Exp Ther Med, 2017, 14(5):4263-4271

PubMed: 29075340 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

World J Clin Oncol, 2017, 8(1):54-66

PubMed: 28246585 ( click the link to review the publication )

Oncotarget, 2017, 9(1):249-267

PubMed: 29416611 ( click the link to review the publication )
Curr Protoc Chem Biol, 2017, 9(2):55-74

PubMed: 28628199 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2016, 143:463-471

PubMed: 27037784 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(12):1240-1252

PubMed: 27791595 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Chin Med J (Engl), 2016, 129(20):2469-2475

PubMed: 27748340 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41811-41824

PubMed: 27248820 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

J Control Release, 2015, 220(Pt B):727-37

PubMed: 26390807 ( click the link to review the publication )

Environ Sci Technol, 2015, 49(6):3575-83

PubMed: 25695909 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(10):1373-87

PubMed: 26276035 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

J Gen Virol, 2013, 94(Pt 12):2750-8

PubMed: 24062531 ( click the link to review the publication )
Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Gynecol Oncol, 2003, 90(3 Pt 2):S16-21

PubMed: 13129491 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfPd25SUUN3ME2wMlAxODJ6NzFOwG0>	NIG0enhUSU6JRWK=
LC-2-ad	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\6TGlEPTB;MD6wNFA{OTdizszN	MmPzV2FPT0WU
RL95-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzJUY1KSzVyPUCuNFAxPjZ6IN88US=>	M4nkTXNCVkeHUh?=
MZ1-PC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLxXpVKSzVyPUCuNFAxPzJ7IN88US=>	NX7B[\|U4W0GQR1XS
TE-8	NFqzbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjxTWM2OD1yLkCwNVE4KM7:TR?=	MVHTRW5ITVJ?
SW954	NIOxcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPjTWM2OD1yLkCwNVE6KM7:TR?=	MlW3V2FPT0WU
TE-11	NVvmb4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP1N3ZpUUN3ME2wMlAxOTJ\|IN88US=>	MWjTRW5ITVJ?
PSN1	NYPlTJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHWTWM2OD1yLkCwNVMh\|ryP	NV\KVmVLW0GQR1XS
MOLT-4	NYnYT486T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\JZXBKSzVyPUCuNFAyPDlizszN	M2riWHNCVkeHUh?=
697	M4m1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMECxOUDPxE1?	NX7K[pdZW0GQR1XS
ETK-1	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC4WnRpUUN3ME2wMlAxOTV{IN88US=>	NIi4O29USU6JRWK=
TE-10	NF\l[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMECxOVQh\|ryP	NXH6[406W0GQR1XS
HUTU-80	M3fOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLjTWM2OD1yLkCwNVY5KM7:TR?=	NIjQcXFUSU6JRWK=
NTERA-S-cl-D1	NWrqfYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMECyNFkh\|ryP	M1u4XXNCVkeHUh?=
MFH-ino	NIXrO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMECyOlgh\|ryP	NWmxR4diW0GQR1XS
IA-LM	M4nORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;oTWM2OD1yLkCwNlgh\|ryP	NHvxOlRUSU6JRWK=
MC116	NYXX[FV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33iUGlEPTB;MD6wNFI5QSEQvF2=	NFzzS2pUSU6JRWK=
RKO	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXyxbm1ZUUN3ME2wMlAxOjl6IN88US=>	M{nP[XNCVkeHUh?=
MRK-nu-1	NV2wd\|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXGTWM2OD1yLkCwNlk6KM7:TR?=	MlTFV2FPT0WU
VA-ES-BJ	NFHxZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMECzJO69VQ>?	NITXRoRUSU6JRWK=
KALS-1	MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LsUGlEPTB;MD6wNFMxQCEQvF2=	NFzzeIhUSU6JRWK=
BB30-HNC	MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn2fFZKSzVyPUCuNFA{OTRizszN	MV3TRW5ITVJ?
ACN	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHYOI1EUUN3ME2wMlAxOzF4IN88US=>	MUPTRW5ITVJ?
TE-9	M1z0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXS0NGl7UUN3ME2wMlAxOzJ4IN88US=>	MkDYV2FPT0WU
SIG-M5	M1jBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PYNWlEPTB;MD6wNFMzPyEQvF2=	MlnZV2FPT0WU
no-10	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2X5emlEPTB;MD6wNFM3OiEQvF2=	NFX2VYNUSU6JRWK=
EW-1	M3\WTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMECzO\|Eh\|ryP	M2fOSnNCVkeHUh?=
SK-LMS-1	NXu5dZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMEC0NFEh\|ryP	M3PuUXNCVkeHUh?=
GT3TKB	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMEC0N\|Qh\|ryP	NIHiN\|BUSU6JRWK=
ES4	M4XadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMEC0OFkh\|ryP	M{OwUHNCVkeHUh?=
IMR-5	NF3Vb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4joeWlEPTB;MD6wNFQ2KM7:TR?=	Ml71V2FPT0WU
NCI-H1648	M{jRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDCTWM2OD1yLkCwOFY6KM7:TR?=	NVfOTpJLW0GQR1XS
MV-4-11	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fwXGlEPTB;MD6wNFQ4PSEQvF2=	MmjIV2FPT0WU
SK-UT-1	M2jG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEC0PEDPxE1?	NHnmW4xUSU6JRWK=
NB13	NFe2cIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnxbHczUUN3ME2wMlAxPDlzIN88US=>	MVvTRW5ITVJ?
DJM-1	MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjURnd2UUN3ME2wMlAxPTNizszN	MXrTRW5ITVJ?
ES8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVWz[mlYUUN3ME2wMlAxPTN6IN88US=>	NV3qcpNEW0GQR1XS
TE-6	M1fpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHjSmZKSzVyPUCuNFA2PyEQvF2=	MYfTRW5ITVJ?
KS-1	M3z5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HqUGlEPTB;MD6wNFU5OiEQvF2=	NVLZSXk3W0GQR1XS
TE-1	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEC2NFYh\|ryP	Mle1V2FPT0WU
ATN-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfWTWM2OD1yLkCwOlA6KM7:TR?=	NV;pUpBLW0GQR1XS
A4-Fuk	NYXHRVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rzS2lEPTB;MD6wNFYyOSEQvF2=	M4\yN3NCVkeHUh?=
ALL-PO	M2ThWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\ERnpKSzVyPUCuNFA3OyEQvF2=	NIPlZpFUSU6JRWK=
BE-13	NGTPTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PtNmlEPTB;MD6wNFY{PiEQvF2=	MYPTRW5ITVJ?
KM12	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEC2N\|ch\|ryP	M2PPOHNCVkeHUh?=
NOS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvHTWM2OD1yLkCwOlUh\|ryP	NV\JcWNjW0GQR1XS
SW962	M4Phcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHH3XnhKSzVyPUCuNFA3PjJizszN	M1PYRXNCVkeHUh?=
OCUB-M	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj6PG5KSzVyPUCuNFA3PjJizszN	NGKwSXBUSU6JRWK=
NCI-H510A	NEfs[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWC0e4ZXUUN3ME2wMlAxPjZ3IN88US=>	NY\WRXhUW0GQR1XS
EW-16	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUf2RY9CUUN3ME2wMlAxPjl2IN88US=>	MUfTRW5ITVJ?
KGN	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnGflFKSzVyPUCuNFA4OTJizszN	MkXWV2FPT0WU
LS-411N	NGP5WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHTTWM2OD1yLkCwO\|E4KM7:TR?=	M{DmS3NCVkeHUh?=
Becker	NHrjWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVriWYxxUUN3ME2wMlAxPzJizszN	MWnTRW5ITVJ?
HC-1	M1zrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEC3NlEh\|ryP	MYXTRW5ITVJ?
CESS	NI\JTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3z4PGlEPTB;MD6wNFc{PyEQvF2=	NFqxOo1USU6JRWK=
KURAMOCHI	NX7LVVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jvZWlEPTB;MD6wNFc1QCEQvF2=	NFLqZ4hUSU6JRWK=
TGBC24TKB	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTENGtrUUN3ME2wMlAxPzV{IN88US=>	NWXteHpLW0GQR1XS
SW982	NFXmSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknkTWM2OD1yLkCwO\|Y3KM7:TR?=	MoGxV2FPT0WU
HCE-4	NV7VcXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7jOJBJUUN3ME2wMlAxPzZ5IN88US=>	M33VS3NCVkeHUh?=
LOUCY	M4XUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTGSoxKSzVyPUCuNFA4PzVizszN	Ml;RV2FPT0WU
8-MG-BA	MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XvRWlEPTB;MD6wNFc6PiEQvF2=	MVvTRW5ITVJ?
HT-144	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3kfFJSUUN3ME2wMlAxQCEQvF2=	NVP1VWQ5W0GQR1XS
LXF-289	MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfwfm9KSzVyPUCuNFA5OThizszN	MXPTRW5ITVJ?
RS4-11	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DYUGlEPTB;MD6wNFg{PiEQvF2=	NF\LOm5USU6JRWK=
DEL	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPPWGNKSzVyPUCuNFA5PDVizszN	MX;TRW5ITVJ?
OCI-AML2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrGfVJKSzVyPUCuNFA5PTJizszN	MnPuV2FPT0WU
CCRF-CEM	NWf1UFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTjNI5JUUN3ME2wMlAxQDdzIN88US=>	MlWyV2FPT0WU
A388	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDZdFk3UUN3ME2wMlAxQDd2IN88US=>	M37YdHNCVkeHUh?=
KNS-42	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TlbmlEPTB;MD6wNFg6OSEQvF2=	NU[2SlFSW0GQR1XS
OVCAR-4	NWC5cpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUSwRYRUUUN3ME2wMlAxQTB2IN88US=>	MVXTRW5ITVJ?
NCI-H1355	NXe0bnlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nkbGlEPTB;MD6wNFkyPCEQvF2=	MnW5V2FPT0WU
BL-70	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIH2SopKSzVyPUCuNFA6OyEQvF2=	MVHTRW5ITVJ?
BL-41	M4Lh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fOS2lEPTB;MD6wNFk{PCEQvF2=	MmHLV2FPT0WU
A101D	NIHib3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHlZ\|lKSzVyPUCuNFA6PiEQvF2=	MnW1V2FPT0WU
HL-60	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjqPINKSzVyPUCuNFA6PjZizszN	MXvTRW5ITVJ?
COR-L279	M2\EN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYewOI5RUUN3ME2wMlAxQTl7IN88US=>	Mnr4V2FPT0WU
NCI-SNU-16	MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7lcI1KSzVyPUCuNFExODhizszN	M4TvcHNCVkeHUh?=
Calu-6	M4e3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEGwNVIh\|ryP	NVjSdlA2W0GQR1XS
SR	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMEGwNlYh\|ryP	MWDTRW5ITVJ?
QIMR-WIL	NWDwcXpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYD3[\|NTUUN3ME2wMlAyODN\|IN88US=>	MkLnV2FPT0WU
LB647-SCLC	MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH34OmNKSzVyPUCuNFExPTFizszN	MoHCV2FPT0WU
RPMI-8226	NF\5WnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PXbGlEPTB;MD6wNVExOiEQvF2=	Ml\wV2FPT0WU
SK-PN-DW	NVPxfVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEGxNVIh\|ryP	NV7LSZhYW0GQR1XS
SF268	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HYOWlEPTB;MD6wNVE2OSEQvF2=	MkT4V2FPT0WU
HD-MY-Z	M1nvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXizTI1HUUN3ME2wMlAyOTZ\|IN88US=>	NGD5NFNUSU6JRWK=
DOHH-2	NF3hVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEGyNFMh\|ryP	NIjqSopUSU6JRWK=
SCC-3	NGjveolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TXXWlEPTB;MD6wNVIxPCEQvF2=	MYXTRW5ITVJ?
ST486	M17Mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTMTWM2OD1yLkCxNlA1KM7:TR?=	NF;VWWxUSU6JRWK=
NALM-6	NH;kOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrSUHVKSzVyPUCuNFEzOTRizszN	MX3TRW5ITVJ?
NCI-H1436	M1z0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT0SmdKSzVyPUCuNFEzOzFizszN	NEf5d4VUSU6JRWK=
KE-37	NYLhOm85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj3UY96UUN3ME2wMlAyOjN2IN88US=>	Ml7jV2FPT0WU
RPMI-8402	NX65WmJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHNTWM2OD1yLkCxNlU3KM7:TR?=	MYTTRW5ITVJ?
RXF393	M{D6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPuTWM2OD1yLkCxNlU4KM7:TR?=	MWrTRW5ITVJ?
KARPAS-45	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwMEGyO{DPxE1?	NGXvUFNUSU6JRWK=
HOP-62	M1XaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXVXXBXUUN3ME2wMlAyOjd4IN88US=>	NILVWZNUSU6JRWK=
ES1	M{\XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjxRlNKSzVyPUCuNFEzQDhizszN	M3;WTHNCVkeHUh?=
L-363	NXrwOHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEGzOVEh\|ryP	NFjOU5FUSU6JRWK=
GI-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojuTWM2OD1yLkCxN\|c{KM7:TR?=	NWOxPWs6W0GQR1XS
CTV-1	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP0TWM2OD1yLkCxOFc5KM7:TR?=	M4n2VXNCVkeHUh?=
TE-5	NXu5SWxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMEG0PVYh\|ryP	MU\TRW5ITVJ?
SNU-C2B	M3PFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rhPWlEPTB;MD6wNVQ6PiEQvF2=	MmX2V2FPT0WU
K-562	NI\4XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX36S4dwUUN3ME2wMlAyPTF4IN88US=>	NUi5VZg3W0GQR1XS
SNB75	Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHyw[lRKSzVyPUCuNFE2PCEQvF2=	MVLTRW5ITVJ?
MOLT-13	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rJT2lEPTB;MD6wNVY{PyEQvF2=	MlnpV2FPT0WU
LS-123	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDlTWM2OD1yLkCxOlY1KM7:TR?=	MUfTRW5ITVJ?
NCI-SNU-5	NVroT4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXQTWM2OD1yLkCxO\|AyKM7:TR?=	MYHTRW5ITVJ?
Daudi	NHnVeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMEG3NFgh\|ryP	NWjZb3hZW0GQR1XS
A253	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMEG3N\|gh\|ryP	MlrDV2FPT0WU
TGBC1TKB	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NESxU2FKSzVyPUCuNFE4PTJizszN	MUjTRW5ITVJ?
SJSA-1	NWrr[GRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrQTWM2OD1yLkCxO\|Y4KM7:TR?=	M4TsenNCVkeHUh?=
NCCIT	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjOXZNFUUN3ME2wMlAyPzZ7IN88US=>	NVvzW4pOW0GQR1XS
NCI-H69	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWL6dWF6UUN3ME2wMlAyPzd6IN88US=>	Mny3V2FPT0WU
SH-4	M1LWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrJTWM2OD1yLkCxPFk2KM7:TR?=	NYL2NZdrW0GQR1XS
HCC1187	NWHMNHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMEG5NlQh\|ryP	NGPGR3ZUSU6JRWK=
HCC1599	NHX1cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMEKwNkDPxE1?	Mn;xV2FPT0WU
ONS-76	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMEKwN\|Yh\|ryP	NEG2bnFUSU6JRWK=
KU812	NUTNfmo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\jTWM2OD1yLkCyNFM6KM7:TR?=	MlHVV2FPT0WU
ML-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrKTWM2OD1yLkCyNFQ4KM7:TR?=	NWnFRoZ4W0GQR1XS
HCE-T	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTvTWM2OD1yLkCyNFkzKM7:TR?=	M1HrWnNCVkeHUh?=
NCI-H446	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3STGhKSzVyPUCuNFIyOTJizszN	M{\XSXNCVkeHUh?=
RPMI-6666	NXnPeIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnxe2twUUN3ME2wMlAzOTR7IN88US=>	MnzhV2FPT0WU
MOLT-16	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:yWIhVUUN3ME2wMlAzOTV\|IN88US=>	MnTGV2FPT0WU
JiyoyeP-2003	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYP3doVkUUN3ME2wMlAzOTd4IN88US=>	MnHIV2FPT0WU
MHH-PREB-1	M4myc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTZZZlsUUN3ME2wMlAzOTlzIN88US=>	MVTTRW5ITVJ?
MC-CAR	NVfhNJRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPtTmtKSzVyPUCuNFI{OjZizszN	M{XMUXNCVkeHUh?=
BC-3	M17ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLYTWM2OD1yLkCyN\|Q1KM7:TR?=	MUnTRW5ITVJ?
KINGS-1	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXYTWM2OD1yLkCyN\|U2KM7:TR?=	Mlm0V2FPT0WU
PF-382	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrXTWM2OD1yLkCyN\|c5KM7:TR?=	NXLqNlNsW0GQR1XS
J-RT3-T3-5	NGLieZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMEKzPFMh\|ryP	MkHwV2FPT0WU
SF539	NI\YTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonGTWM2OD1yLkCyOFAyKM7:TR?=	M{WyVHNCVkeHUh?=
LB831-BLC	NVTSNYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoOwTWM2OD1yLkCyOFg2KM7:TR?=	MYXTRW5ITVJ?
DMS-114	NIjPSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMEK1NFIh\|ryP	MY\TRW5ITVJ?
LB1047-RCC	M1nrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LkZ2lEPTB;MD6wNlUyKM7:TR?=	M{j2fnNCVkeHUh?=
LB771-HNC	M17TRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnxUJliUUN3ME2wMlAzPTN2IN88US=>	M{PDc3NCVkeHUh?=
BB65-RCC	NVK4VYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIL6eI5KSzVyPUCuNFI2OzRizszN	NU\0Z5N3W0GQR1XS
BV-173	NWXz[2pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmexTWM2OD1yLkCyOVU1KM7:TR?=	M17Nd3NCVkeHUh?=
ARH-77	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHyO2d7UUN3ME2wMlAzPjBzIN88US=>	M1nLfHNCVkeHUh?=
IST-MEL1	NUnPOmd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlSxTWM2OD1yLkCyOlI{KM7:TR?=	MnXkV2FPT0WU
NB1	NE\wfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETROVhKSzVyPUCuNFI3QDdizszN	NEnTRoNUSU6JRWK=
EoL-1-cell	NXT1doZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDqPXRQUUN3ME2wMlAzPjh6IN88US=>	MV\TRW5ITVJ?
KY821	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInzfHRKSzVyPUCuNFI3QTdizszN	NIjYTYRUSU6JRWK=
CMK	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XNe2lEPTB;MD6wNlc{PCEQvF2=	NIDsS3ZUSU6JRWK=
NCI-H2126	NEHiTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUixZoRvUUN3ME2wMlAzPzZ6IN88US=>	M2HaRXNCVkeHUh?=
NCI-H526	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfOOJF7UUN3ME2wMlAzQDlzIN88US=>	MYPTRW5ITVJ?
COLO-684	M1y1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmj6TWM2OD1yLkCyPVA5KM7:TR?=	MoPIV2FPT0WU
NCI-H747	NF7rcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3G5U2lEPTB;MD6wNlk{OyEQvF2=	NWPDVpRIW0GQR1XS
JAR	NEnmOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXPTWM2OD1yLkCyPVQ3KM7:TR?=	MXLTRW5ITVJ?
MEG-01	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXKTWM2OD1yLkCyPVc5KM7:TR?=	MYjTRW5ITVJ?
MONO-MAC-6	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEOwNlMh\|ryP	MX\TRW5ITVJ?
IST-SL1	M1S5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXwTWM2OD1yLkCzNFQzKM7:TR?=	MV7TRW5ITVJ?
CPC-N	NUe2OpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEOwO\|kh\|ryP	MW\TRW5ITVJ?
NCI-H1963	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfIfXRUUUN3ME2wMlA{OTNzIN88US=>	M4\vd3NCVkeHUh?=
K052	NIfDd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMEOyOFch\|ryP	Mlv5V2FPT0WU
KM-H2	M2DLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLBTWM2OD1yLkCzN\|A4KM7:TR?=	M4\UcnNCVkeHUh?=
TE-12	NVPy[21jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvaTWM2OD1yLkCzN\|A6KM7:TR?=	MVjTRW5ITVJ?
TK10	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYWwWmdEUUN3ME2wMlA{OzV4IN88US=>	MWXTRW5ITVJ?
NMC-G1	M4PpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMEO0OVIh\|ryP	MlOyV2FPT0WU
no-11	M4TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PYXGlEPTB;MD6wN\|Q4QCEQvF2=	Mn71V2FPT0WU
NCI-H524	NInLcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMEO1Nlkh\|ryP	MlmxV2FPT0WU
MHH-CALL-2	NGXHeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXvXm9KSzVyPUCuNFM2PjJizszN	M{i4NHNCVkeHUh?=
GB-1	M{HsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\WPVFnUUN3ME2wMlA{PiEQvF2=	M3vtUXNCVkeHUh?=
OPM-2	NVvZb4oyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljuTWM2OD1yLkCzOlc{KM7:TR?=	MWPTRW5ITVJ?
RH-1	NWL6XJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMEO4NVkh\|ryP	NHvtZpRUSU6JRWK=
NCI-H64	NXO1TpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\OS2lEPTB;MD6wN\|g2PyEQvF2=	Mk\lV2FPT0WU
EVSA-T	NWHaNXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M364bWlEPTB;MD6wN\|kzOyEQvF2=	NFjkO21USU6JRWK=
KARPAS-299	NHKw[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XZSWlEPTB;MD6wN\|k5KM7:TR?=	NELaXXhUSU6JRWK=
MZ7-mel	M2rpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M123cmlEPTB;MD6wOFA1KM7:TR?=	NU\NbVVuW0GQR1XS
LB373-MEL-D	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnVNokzUUN3ME2wMlA1OTB3IN88US=>	MWnTRW5ITVJ?
HEL	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMESxOEDPxE1?	MkLnV2FPT0WU
SW872	MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFm0NlVKSzVyPUCuNFQzOSEQvF2=	Mnr6V2FPT0WU
DU-4475	M4T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;QTWM2OD1yLkC0NlQ1KM7:TR?=	MYXTRW5ITVJ?
IST-SL2	MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PwdWlEPTB;MD6wOFI4PSEQvF2=	M3\rR3NCVkeHUh?=
NCI-H82	NGnNbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\kWoJXUUN3ME2wMlA1OzB5IN88US=>	MW\TRW5ITVJ?
LC4-1	M3q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7X[YZ{UUN3ME2wMlA1OzVzIN88US=>	MWLTRW5ITVJ?
HDLM-2	NWT1SmptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMESzPVIh\|ryP	M4nGOnNCVkeHUh?=
MMAC-SF	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPq[mN5UUN3ME2wMlA1PTN2IN88US=>	NFX4XWFUSU6JRWK=
L-540	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3DVVZRUUN3ME2wMlA1PjN7IN88US=>	NHTtTpRUSU6JRWK=
MZ2-MEL	M3juc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMES3OFIh\|ryP	NF\6dFNUSU6JRWK=
LU-134-A	NXz3fZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMES3O\|Mh\|ryP	MXzTRW5ITVJ?
UACC-257	NWDLbXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPFTWM2OD1yLkC0PFQ6KM7:TR?=	MlPpV2FPT0WU
NCI-H1581	M1jkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjKTWM2OD1yLkC0PVU{KM7:TR?=	Ml70V2FPT0WU
NB17	M4T4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\xSpRKSzVyPUCuNFQ6PzlizszN	NUjucXlNW0GQR1XS
SBC-1	NXq5c5Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moj4TWM2OD1yLkC1NFQzKM7:TR?=	MmPZV2FPT0WU
TALL-1	M3XMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[1OlJKSzVyPUCuNFUxPDVizszN	M1XxVHNCVkeHUh?=
NCI-H1304	M{W4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMEWyNFgh\|ryP	NYfYU2pLW0GQR1XS
NEC8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrnTWM2OD1yLkC1Nlg3KM7:TR?=	NGj6dVBUSU6JRWK=
CAL-148	NXv5fpNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;LPFJ7UUN3ME2wMlA2PDN7IN88US=>	M3TQOnNCVkeHUh?=
CGTH-W-1	NFzOOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7t[ndKSzVyPUCuNFU1PDlizszN	MUPTRW5ITVJ?
NCI-H889	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPmXYtKSzVyPUCuNFU2QTJizszN	NUXYe3ZsW0GQR1XS
GR-ST	NWjvWW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHiTWM2OD1yLkC1OlIyKM7:TR?=	NFToVWdUSU6JRWK=
KARPAS-422	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPWRZVKSzVyPUCuNFU3PSEQvF2=	M3XyZ3NCVkeHUh?=
RPMI-8866	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;GXY5KSzVyPUCuNFU4OTJizszN	Ml\rV2FPT0WU
SCLC-21H	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMEW4PFQh\|ryP	MorqV2FPT0WU
COR-L88	M{j5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEW5Nlch\|ryP	NGTicoNUSU6JRWK=
LU-139	M1LlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzvTlhKSzVyPUCuNFU6QDZizszN	Mor0V2FPT0WU
SF126	NU[x[mFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfLZplIUUN3ME2wMlA3OTN\|IN88US=>	NWO0Z2RzW0GQR1XS
NCI-H1882	Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHKTWM2OD1yLkC2OFI1KM7:TR?=	M{LuTHNCVkeHUh?=
EW-24	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwME[0PFMh\|ryP	M4H4TnNCVkeHUh?=
CP67-MEL	M3zsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofyTWM2OD1yLkC2PFEh\|ryP	M2HpcnNCVkeHUh?=
DG-75	M4TQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYewWmU3UUN3ME2wMlA3QDl7IN88US=>	MU\TRW5ITVJ?
LOXIMVI	NX7EPIsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrKUY9kUUN3ME2wMlA4ODJ6IN88US=>	NXHwZYV3W0GQR1XS
HH	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEexOVch\|ryP	NUeze2ZxW0GQR1XS
K5	NHnkWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEeyNlYh\|ryP	M123OnNCVkeHUh?=
EC-GI-10	NEj1eXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDGTWM2OD1yLkC3NlU4KM7:TR?=	MXfTRW5ITVJ?
SK-N-DZ	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGGwOHJKSzVyPUCuNFc{ODdizszN	MoTnV2FPT0WU
A3-KAW	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLVTWM2OD1yLkC3N\|UyKM7:TR?=	NXv5[mRoW0GQR1XS
MLMA	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vFdmlEPTB;MD6wO\|Q3PSEQvF2=	NGrEWY9USU6JRWK=
LB996-RCC	NIXTdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;JNGlEPTB;MD6wO\|cxPyEQvF2=	M{XZVXNCVkeHUh?=
OS-RC-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlz5TWM2OD1yLkC3O\|Q5KM7:TR?=	M1\GenNCVkeHUh?=
CTB-1	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzHRnVrUUN3ME2wMlA4QDFizszN	MWTTRW5ITVJ?
IST-MES1	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDOSYFKSzVyPUCuNFc6OTJizszN	NFXJemZUSU6JRWK=
LS-1034	NXjRNYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rTXWlEPTB;MD6wPFA{PSEQvF2=	M4nqPHNCVkeHUh?=
HT	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHWTWM2OD1yLkC4NFg3KM7:TR?=	MUXTRW5ITVJ?
NCI-H2141	MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMEixJO69VQ>?	NU\kbXlvW0GQR1XS
LB2518-MEL	M{[xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXofndPUUN3ME2wMlA5OTRzIN88US=>	NIS1RpNUSU6JRWK=
GI-ME-N	NIH4ZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDYXFJKSzVyPUCuNFg1PTJizszN	NXHDRVZZW0GQR1XS
TGW	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7pTWM2OD1yLkC4OlA4KM7:TR?=	NHHvfG9USU6JRWK=
SK-NEP-1	M{HhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMEi2OFEh\|ryP	NUD1TFd{W0GQR1XS
NOMO-1	NGrrT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjlTWM2OD1yLkC5Nlc2KM7:TR?=	NWTHfYNpW0GQR1XS
ES6	M{nJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PrVWlEPTB;MD6wPVU5QSEQvF2=	MUPTRW5ITVJ?
NCI-H209	M{T0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfkfWpKUUN3ME2wMlA6Pzh4IN88US=>	MYfTRW5ITVJ?
GAK	NI\1dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HCSWlEPTB;MD6xNFE3KM7:TR?=	MYXTRW5ITVJ?
BC-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknsTWM2OD1yLkGwN\|YyKM7:TR?=	M{KwR3NCVkeHUh?=
KLE	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfFXIVKSzVyPUCuNVA1PDNizszN	M3PUOHNCVkeHUh?=
EW-3	MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[wOXJ4UUN3ME2wMlExQThizszN	NIPMXWtUSU6JRWK=
NKM-1	NXXYcVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMUGxJO69VQ>?	Mn:yV2FPT0WU
D-336MG	MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInJXYVKSzVyPUCuNVEzPDRizszN	NHPzW2ZUSU6JRWK=
NB69	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3pdYp5UUN3ME2wMlEyOzBzIN88US=>	NGG4eIZUSU6JRWK=
D-263MG	NYjGdHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\Nd5pKSzVyPUCuNVE4OTJizszN	NHvkNpNUSU6JRWK=
KP-N-YS	M4LE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfNTWM2OD1yLkGyNlkyKM7:TR?=	NWDmPHRmW0GQR1XS
NCI-H1155	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\CTWM2OD1yLkGyOVU5KM7:TR?=	M1vBRXNCVkeHUh?=
BOKU	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMUK1O\|kh\|ryP	NECwSoFUSU6JRWK=
LAMA-84	NI\qWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\GRolNUUN3ME2wMlEzQTlizszN	MkLWV2FPT0WU
Raji	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LvWmlEPTB;MD6xN\|EyPyEQvF2=	NUHIVpN3W0GQR1XS
LU-65	NXP2fW5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XFV2lEPTB;MD6xN\|MxPyEQvF2=	NWXDPYlXW0GQR1XS
NCI-H187	NEiy[\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVu4W\|lEUUN3ME2wMlE{QTJ2IN88US=>	NVzLc3dTW0GQR1XS
GCIY	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMUS5NFEh\|ryP	MkDsV2FPT0WU
NCI-H2107	M{HtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1O4T2lEPTB;MD6xOVA5KM7:TR?=	MWfTRW5ITVJ?
NCI-H1522	NE\jOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPDTWM2OD1yLkG1NlY3KM7:TR?=	NV31blZ2W0GQR1XS
NB6	M3O4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX1TYhzUUN3ME2wMlE2PjJ\|IN88US=>	M1vkZ3NCVkeHUh?=
EM-2	NHm1bJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMUW3NFYh\|ryP	Mm\zV2FPT0WU
HCC2218	M1vXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMUW5PEDPxE1?	MmKwV2FPT0WU
NCI-H748	M{fEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y5NmlEPTB;MD6xOlM4PiEQvF2=	MVvTRW5ITVJ?
MS-1	M3PNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDsTWM2OD1yLkG2OVM4KM7:TR?=	M2ftUnNCVkeHUh?=
NB5	NX\3UYpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMU[1PVch\|ryP	NF3YWYNUSU6JRWK=
OMC-1	NHXLSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMU[2PFgh\|ryP	NU\QbYtqW0GQR1XS
NCI-H345	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXZTm5{UUN3ME2wMlE3QTJ6IN88US=>	M4KybnNCVkeHUh?=
L-428	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vZUWlEPTB;MD6xOlk1PSEQvF2=	NYizNVQ4W0GQR1XS
SCH	NELJO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMUi2PFUh\|ryP	M4[ycHNCVkeHUh?=
NCI-H1417	NXjUeGN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDuTIRKSzVyPUCuNVkzOjdizszN	M1fEU3NCVkeHUh?=
COLO-320-HSR	NEjHXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjSTWM2OD1yLkG5OVMzKM7:TR?=	MmTkV2FPT0WU
BT-474	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\yTWM2OD1yLkKwPFkzKM7:TR?=	Mm\YV2FPT0WU
GDM-1	MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLIeJBwUUN3ME2wMlIyQTdzIN88US=>	MXjTRW5ITVJ?
NCI-H2196	M13wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1m5TWlEPTB;MD6yNlI{PSEQvF2=	Mn7jV2FPT0WU
KP-N-RT-BM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTNV2hxUUN3ME2wMlIzOzR7IN88US=>	M3rrc3NCVkeHUh?=
KNS-81-FD	Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDIS2lIUUN3ME2wMlIzQTV6IN88US=>	NX;NXnlZW0GQR1XS
COLO-668	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3y3WGlEPTB;MD6yN\|Y4PSEQvF2=	NWLwOnZwW0GQR1XS
C2BBe1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LEdWlEPTB;MD6yOlc1PyEQvF2=	NH;GcmhUSU6JRWK=
Ramos-2G6-4C10	M3jZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXK[3FKSzVyPUCuNlY6PTRizszN	M{HaNXNCVkeHUh?=
CAS-1	NUDRZ3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L3[WlEPTB;MD6yO\|A6PiEQvF2=	Mmi3V2FPT0WU
GOTO	NFPUbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMke4PVQh\|ryP	MkixV2FPT0WU
LP-1	NIWwWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMkiwOVch\|ryP	NVfkW4V[W0GQR1XS
NCI-SNU-1	MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMkm0NlIh\|ryP	MX7TRW5ITVJ?
EB-3	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmG3TWM2OD1yLkK5PVc6KM7:TR?=	M3XxT3NCVkeHUh?=
MHH-NB-11	NHfIPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq4Rm1KSzVyPUCuN\|A1ODJizszN	MUHTRW5ITVJ?
SK-N-FI	MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TvbGlEPTB;MD6zNVY6OiEQvF2=	Mm\yV2FPT0WU
HCC2157	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;WSnVKSzVyPUCuN\|M6OTNizszN	M3qyZ3NCVkeHUh?=
SIMA	Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwM{S1PFEh\|ryP	M{D3RXNCVkeHUh?=
MDA-MB-134-VI	NX;qRW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwM{[5Nlgh\|ryP	MUnTRW5ITVJ?
NCI-H1694	NImwWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwM{eg{txO	MV\TRW5ITVJ?
EHEB	NFjOZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwM{mwPFUh\|ryP	M1rOWHNCVkeHUh?=
U-266	M17vSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPWNFB1UUN3ME2wMlM6QDR4IN88US=>	MmfPV2FPT0WU
LC-1F	NH:wdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDab4hIUUN3ME2wMlQ{PzZ3IN88US=>	NY\2fJA5W0GQR1XS
SHP-77	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwNEe4OVUh\|ryP	Mn\rV2FPT0WU
LS-513	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LFcGlEPTB;MD60PVMxPyEQvF2=	NYrGbGdEW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[4]

- Collapse

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

- Collapse

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973
Smiles	CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C4=CC=CC=C4)C5(O)CC(OC(=O)C(O)C(NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)C(=C1C5(C)C)C

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04000906	Not yet recruiting	Drug: NAB paclitaxel\|Drug: Cisplatin	Peritoneal Carcinomatosis	University Hospital Geneva	September 2019	Phase 1
NCT04046887	Not yet recruiting	Drug: Lonsurf\|Drug: Gemcitabine\|Drug: Nab-Paclitaxel	Pancreatic Cancer\|Pancreatic Ductal Adenocarcinoma	Patrick Joseph Loehrer Sr.\|Indiana University\|Taiho Oncology Inc.	August 2019	Phase 1
NCT03779464	Recruiting	Drug: S1 or Gemcitabine	Pancreatic Cancer\|Nab-paclitaxel\|Gemcitabine\|S1	Wuhan Union Hospital China	August 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel